My tenure on the BLSI
board was a short one in 2003, but I have watched the Company with great interest and I am impressed with the Company's progress led by the current directors, officers and principal shareholders during the past two years.
Under the research agreements BLSI
has agreed to fund three-year sponsored research programs for approaches to activate pro-regenerative pathways that stimulate axon regeneration led by Dr.
Since 1992, BLSI
has raised more than $65 million to fund its research programs, which are primarily conducted at Harvard Medical School and its affiliated medical centers.
The Company believes that this designation could provide BLSI considerable strategic advantages.
BLSI Contacts: Meredith Patin - Investors 508-497-2360 ext.
also announced that Mark Hurtt, Chief Medical Officer of Boston Life Sciences, Inc.
Savas went on to say, "We thank Joe Hernon for his contributions to BLSI
throughout the last eight years.
The licensing of Cethrin enables us to continue toward our goal of transforming BLSI into a CNS-focused therapeutics company.
According to BLSI Chief Medical Officer, Mark Hurtt, "We believe the early efficacy findings are promising.
We appreciate the many contributions that Marc has made since founding BLSI
in 1992," stated Peter G.
Bianchine brings extensive experience in medicine and clinical pharmacology to BLSI